Figure 4.

Effect of Neoadjuvant GMCI on Inhibitory/Activation Markers in CD8⁺ TILs

Left panels: using the same samples as described in Figure 2, the expression of five inhibitory/activation markers (PD-1, CD39, CTLA-4, TIM3, and TIGIT) on CD8⁺ T cells in the pre-Rx samples were compared to post-Rx tumor samples. Paired t tests were applied to define the statistical significance (p value) of the changes. Right panels: the percentages of specific markers on CD8⁺ T cells from the current study (Ad.TK) were compared with values from a recent independent study,²⁴ where TIL phenotype and function were analyzed in 44 early-stage lung cancers using the same flow cytometry panels and protocols (control samples). Student’s t tests were applied to define the statistical significance (p value) of the differences.